Syntegon has entered a strategic partnership with Bayer for the development of new continuous manufacturing processes for oral solid dosage (OSD) forms.   The cooperation is based on the Xelum platform developed by the Syntegon subsidiary Hüttlin, which the partners intend to advance together and establish as a standard in the pharmaceutical industry.   Its main advantage and a novelty in continuous pharmaceutical production is the previously unattained precise dosing of active ingredients. ...